Advancing
cancer research

The latest publications and guidelines from the RECIST working group.

Publications

Explore our latest research and findings in cancer metrics.

DateTitleAuthorsPublicationVolumeIssuePages
2024Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working groupWyatt AW, Litière S, Bidard FC, Cabel L, Dyrskjøt L, Karlovich CAClinical Cancer Research
2024Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group. JCO Precis Oncol.Nakajima EC, Simpson A, Bogaerts J, de Vries EGE, Do R, Garalda EJCO Precision Oncology8Online onlyOnline only
2023Towards evidence-based response criteria for cancer immunotherapyElena Garralda, Scott A. Laurie, Lesley Seymour & Elisabeth G. E. de VriesNature Reviews Clinical143001
2023Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor ResponseLalitha K Shankar, Erich Huang, Saskia Litiere, Otto S Hoekstra, Larry Schwartz, Sandra ColletteCancer Research and Treatment82234441–4452
2019RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisLitiere S, Isaac G, de Vries E, Bogaerts J, Chen A, Dancey JJournal of Clinical Oncology37131102-1110
2017iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsProf Lesley Seymour, Jan Bogaerts, PhD, Andrea Perrone, MD, Robert FordThe Lancet Oncology183e143-e152
2017RECIST - learning from the past to build the futureSaskia Litière, Sandra Collette, Elisabeth G. E. de Vries, Lesley Seymour & Jan BogaertsNature Reviews Clinical143187-192
2016RECIST 1.1 - Standardisation and Disease Specific Adaptations: Perspectives from the RECIST Working GroupLawrence H. Schwartz, Lesley Seymour, Saskia Litière, Robert Ford, Stephen Gwyther, Sumithra MandrekarEuropean Journal of Cancer62138-145
2016RECIST 1.1 - Update and Clarification: From the RECIST CommitteeLawrence H. Schwartz, Saskia Litière, Elisabeth de Vries, Robert Ford, Stephen Gwyther, Sumithra MandrekarEuropean Journal of Cancer62132-137
2015Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsMing-Wen An, Yu Han, Jeffrey P. Meyers, Jan Bogaerts, Daniel J. Sargent and Sumithra J. MandrekarJournal of Clinical Oncology33344048-4057
2015Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall SurvivalMing-Wen An, Xinxin Dong, Jeffrey Meyers, Yu Han, Axel Grothey, Jan BogaertsJournal of the National Cancer Institute10711
2014Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data WarehouseSumithra J. Mandrekar, Ming-Wen An, Jeffrey Meyers, Axel Grothey, Jan Bogaerts and Daniel J. SargentJournal of Clinical Oncology328841-850
2014Reply to Verlingue, Koscielny and FerteLitiere S., De Vriese E.G.E., Seymour L., Sargent D., Shankar L., Bogaerts J.European Journal of Cancer50162889-2891
2014The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology communityLiu Y., Litiere S., De Vriese G., Sargent D., Shankar L., Bogaerts J., European Journal of Cancer502260-266
2014Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data WarehouseMandrekar S.J., An M., Meyers J., Grothey A., Bogaerts J., Sargent D.J. Journal of Clinical Oncology328841-852
2014The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 databaseLitiere S., De Vries E., Seymour L., Sargent D., Shankar L., Bogaerts J.European Journal of Cancer501847-1853
2009Evaluation of lymph nodes with RECIST 1.1Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., Eisenhauer E.A.European Journal of Cancer452261-267
2009Lessons learned from independent central reviewSchwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S.European Journal of Cancer452268-274
2009Optimising the design of phase II oncology trials: The importance of randomisationRatain M.J., Sargent D. J.European Journal of Cancer452275-280
2009Editorial boardEuropean Journal of Cancer452ii
2009Validation of novel imaging methodologies for use as cancer clinical trial end-pointsSargent D.J., Rubinstein L., Schwartz L., Dancey J.E., Gatsonis C., Dodd L.E.European Journal of Cancer452290-299
2009A simulation study to evaluate the impact of the number of lesions measured on response assessmentMoskowitz C.S., Jia X., Schwartz L.H., Gönen M.European Journal of Cancer452300-310
2009Recommendations for the assessment of progression in randomised cancer treatment trialsDancey J.E., Dodd L.E., Ford R., Kaplan R., Mooney M., Rubinstein LEuropean Journal of Cancer452281-289
2009Cancer clinical trial outcomes: Any progress in tumour-size assessment?Verweij J., Therasse P., Eisenhauer E.European Journal of Cancer452225-227
2009Individual patient data analysis to assess modifications to the RECIST criteriaBogaerts J., Ford R., Sargent D., Schwartz L.H., Rubinstein L., Lacombe D.European Journal of Cancer452248-260
2009New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R.European Journal of Cancer452228-247
2000New Guidelines to Evaluate the Response to Treatment in Solid TumorsTherasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L.Journal of the National Cancer Institute923205-216